Vermont AG Issues Subpoena to Novartis for 340B Documents and Information

Novartis is the second known drug manufacturer subpoenaed by the Vermont attorney general over manufacturer denials of or restrictions on 340B pricing for drugs shipped to contract pharmacies.

Vermont’s top law enforcement official has asked a second drug manufacturer—Novartis—for documents and information concerning the company’s participation in the 340B program in the state.

Tuesday in its interim financial report for the first quarter of 2021, the Swiss

Read More »

NY State 340B Providers Get More Time to Challenge Reimbursement Change

New York lawmakers and Gov. Andrew Cuomo agreed on budget legislation this week that will delay a Medicaid drug benefit transfer opposed by 340B entities for two years.

New York state lawmakers and Gov. Andrew Cuomo (D) agreed this week to postpone transferring Medicaid managed care prescription drug  benefits to Medicaid fee for service (FFS) for two years, temporarily averting a significant financial loss to 340B covered entities.

Read More »

340B Entities Keeping Watch on Bills to Create State Drug Affordability Boards

The Colorado General Assembly is one of nine state legislatures considering bills to create state drug affordability boards.

Nine states are considering legislation to create boards to review prescription drug prices and intervene to lower them if drugs become too expensive or if their prices spike. Although the bills’ implications for the 340B program have not been fully

Read More »

Utah Might Soon Outflank Express Scripts’ New 340B Requirement

Utah lawmakers have passed and sent to the governor a bill that would forbid insurers or their PBMs from forcing federally qualified health centers to include modifiers on claims identifying drugs as being 340B purchased, Medicaid claims excepted.

Pharmacy benefits manager Express Scripts’ (ESI) new pharmacy reporting requirement for reclassifying a previously submitted prescription drug claim as 340B-eligible “applies to the extent not prohibited by law,” the PBM says in an FAQ on its website.

ESI’s statement in

Read More »

State Activity to Rein in PBM Discrimination Against 340B Entities Heats Up

Tennessee is one of at least six states weighing legislation to forbid PBM discrimination against 340B covered entities.

At least six states have introduced or passed bills in recent weeks that would forbid pharmacy benefit managers from discriminating against 340B covered entities regarding reimbursements and other practices.

The bills range from 340B-specific legislation to broader bills to address

Read More »

News Flash: State Attorney General Orders Sanofi to Hand Over 340B Information

So far, none of the other drug companies denying or imposing conditions on 340B pricing on contract pharmacy drugs have publicly reported being subpoenaed by Vermont Attorney General T.J. Donovan.

Vermont State Attorney General T.J. Donovan (D) has issued a subpoena to drug manufacturer Sanofi “seeking certain information about Sanofi’s 340B program participation,” the company disclosed last week.

Neither Sanofi nor Donovan’s office have responded to requests for comment. Sanofi

Read More »

N.Y. and Calif. 340B Pharmacies Get Reprieve From Medicaid Cuts

New York State and California’s nationally watched efforts to transfer their pharmacy programs for low-income individuals from Medicaid managed care to Medicaid fee for service (FFS)—both scheduled to take effect on April 1—have been temporarily placed on hold. The states

Read More »

Indiana House to Vote on Stopping PBMs From Squeezing 340B Entities

An Indiana House committee last week unanimously passed a bill to stop pharmacy benefit managers (PBMs) from discriminating against 340B covered entities.

State Rep. Edward Clere’s (R) bill, HR 1393, is now before the full House. There is no

Read More »

Calif. Health Centers Ask Newsom to Delay Medi-Cal Drug Benefit Shift Until 2022

California health centers have asked Gov. Gavin Newsom to delay the transfer of Medicaid managed care drug benefits to Medicaid fee for service until next year.

California health centers asked Gov. Gavin Newsom (D) on Friday to delay implementing his controversial transfer of Medicaid drug benefits from managed care to fee for service until January 2022, to let health centers “focus on the needs of their

Read More »

44 New York State Lawmakers Urge Cuomo to Reverse Medicaid Drug Benefit Transfer

Forty-four New York state legislators have signed a letter to Gov. Andrew Cuomo (D) expressing “strong opposition” to the scheduled transfer in April of Medicaid managed care pharmacy benefits to Medicaid fee for service. They said the transfer “will have

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live